Johnson & Johnson Ends Dengue Study
This is a news story, published by Yahoo Finance, that relates primarily to Johnson & Johnson news.
drug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Dengue fever. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest dengue virus news, detectable dengue virus news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
dengue diseaseReuters
•J&J discontinues dengue drug study after changes in R&D portfolio
81% Informative
Johnson & Johnson discontinue field study of its experimental pill for prevention of dengue.
Drugmaker reprioritized its communicable diseases R&D portfolio.
No safety issues were identified for the drug, mosnodenvir, the company said.
Dengue fever is also known as "break bone fever" for the severity of the joint pain and spasms some patients experience.
VR Score
91
Informative language
97
Neutral language
81
Article tone
formal
Language
English
Language complexity
68
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links